Physician profile
Efrain D Salgado
NPI 1699739029
$2,589.91
in general payments reported to CMS, 2019-2025
34 companies · $77.53 in 2025
The $77.53 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2020: $254 · 2021: $378 · 2022: $391 · 2023: $496 · 2024: $606 · 2025: $77.53.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,179.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $344.52 | 2022-2025 | Botox, Ubrelvy |
| Genentech USA, INC. | $267.30 | 2019-2023 | Ocrevus |
| Neurocrine Biosciences, INC. | $261.82 | 2022-2024 | Ingrezza, Ongentys |
| Novartis Pharmaceuticals Corporation | $151.33 | 2019-2021 | |
| Emd Serono, INC. | $140.87 | 2022-2023 | Mavenclad |
| Takeda Pharmaceuticals U.S.A., INC. | $115.31 | 2023-2024 | Gammagard |
| Biogen, INC. | $115.04 | 2019-2024 | Tysabri, Vumerity, Plegridy |
| Alexion Pharmaceuticals, INC. | $113.20 | 2022-2025 | Ultomiris, Soliris |
| Ucb, INC. | $106.34 | 2020-2025 | Nayzilam |
| Lundbeck LLC | $105.93 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $99.86 | 2021 | |
| Allergan, INC. | $73.75 | 2019-2020 | |
| Argenx US, INC. | $68.36 | 2023-2024 | Vyvgart, Vyvgart Hytrulo |
| Adamas Pharmaceuticals, INC. | $61.98 | 2019-2021 | |
| Banner Life Sciences, LLC | $58.33 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $48.10 | 2023-2024 | Wainua |
| E.R. Squibb & Sons, L.L.C. | $47.29 | 2020-2021 | |
| Sunovion Pharmaceuticals INC. | $41.89 | 2022 | |
| Sk Life Science, INC. | $36.98 | 2020-2021 | |
| Mdd US Operations, LLC | $36.49 | 2024 | Apokyn |
| Revance Therapeutics, INC. | $29.20 | 2024 | Daxxify |
| Jazz Pharmaceuticals INC. | $26.52 | 2022 | |
| Tanabe Pharma America, INC. | $22.90 | 2020 | |
| Xeris Pharmaceuticals, INC. | $22.00 | 2022 | |
| Aquestive Therapeutics, INC. | $21.47 | 2021 | |
| Neurelis, INC. | $21.47 | 2024 | Valtoco |
| Boston Scientific Corporation | $21.41 | 2022 | |
| Kyowa Kirin, INC. | $21.10 | 2021 | |
| Amgen INC. | $21.08 | 2019 | |
| Merz Pharmaceuticals, LLC | $20.83 | 2023 | Xeomin |
| Pfizer INC. | $20.38 | 2023 | |
| Acorda Therapeutics, INC | $18.31 | 2019 | |
| Amneal Pharmaceuticals LLC | $16.17 | 2019 | |
| Lilly USA, LLC | $12.38 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Efrain Salgado listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.